15 Jun 17

Ardea Biosciences fourth one fourth net loss decreases to $0.6 million Ardea Biosciences, Inc medisinering informasjon . , a biotechnology organization focused on the development of small-molecule therapeutics for the treatment of serious diseases, reported latest accomplishments and announced 4th quarter and full-year 2010 financial results. ‘With approximately $160 million in money as of the end of February, we are in an excellent budget,’ commented Barry D. Quart, PharmD, Ardea's president and ceo.in December 2010 ‘ Latest Accomplishments and Important Upcoming Events, america Adopted Brands Counsel used lesinurad, pronounced ‘le sin' ure ad’, as the USAN name for RDEA594. In 2011 January, we announced positive, topline results from a Phase 2b study adding lesinurad to allopurinol in 208 allopurinol-refractory patients.

kjøp cialis

Arcam receives order for Arcam Q10 system from Implantcast in Germany Arcam, listed on NASDAQ OMX , provides received an purchase for an Arcam Q10 program from Implantcast in Germany. The operational system will be used for production of orthopedic implants. Implantcast is an implant producer with head office in Buxtehude, southwest of Hamburg. Implantcast comes with an extensive selection of orthopedic products, with both patient-specific and standard implants. The above info has been made open public in accordance with the Securities Market Act and/or the Financial Instruments Trading Take action. The information was released on July 2, 2013.